CAMP4 Therapeutics Corporation — Form 8-K Summary
Reporting date: September 28, 2026. This current report covers an Analyst Day and updates on the planned ASCEND trial and pipeline. The Item 7.01 information and exhibits are furnished, not deemed filed for Exchange Act Section 18 purposes, except as expressly incorporated by reference.
Business context and key updates
CAMP4 is a biotechnology company developing treatments for haploinsufficient disorders. The filing describes clinical and preclinical programs; it does not report quarterly or annual financial results.
- CMP-002 / ASCEND: Planned Phase 1/2 randomized, double-blind, placebo-controlled multiple-ascending-dose study in SYNGAP1-related disorder (SRD). Participants will be randomized 3:1 to intrathecal CMP-002 or a sham pinprick procedure. Three dose cohorts are planned, with at least eight participants per cohort, followed by an open-label extension.
- The study is designed for participants aged 2 to under 18 with genetically confirmed protein-truncating SYNGAP1 mutations in exons 5–19 and specified clinical features. Certain non-truncating variants and safety-related conditions are excluded.
- Planned duration is approximately 10 months per participant, including screening, baseline, three doses over about three months, and follow-up over about six months. Assessments include safety, pharmacokinetics, seizure and sleep measures, and exploratory measures of motor function, communication, behavior, development and cognition.
- The company plans to conduct the trial at more than 11 sites across at least nine countries. Sites in the United Kingdom, Australia and Argentina have regulatory approval; European Union sites remain under regulatory and ethics review.
- Pipeline: CAMP4 is advancing a preclinical SHANK3 program for Phelan-McDermid Syndrome and expects to select a development candidate in 2027. The company estimates more than 45,000 patients with the syndrome in the United States. It is also evaluating two additional early-stage CNS haploinsufficiency programs.
Financial condition and period comparisons
The filing provides no revenue, profit or loss, cash flow, margin, debt, liquidity, or other financial metrics, and no comparison with a prior period. It notes that CAMP4 has incurred substantial losses since inception, expects substantial and increasing losses for the foreseeable future, and needs substantial additional financing to achieve its goals.
Outlook, risks and contingencies
- The company expects to dose the first ASCEND participant by the end of 2026 and targets topline data in the first half of 2028. These are forward-looking targets, not guarantees.
- The company says its planned dose levels fall within an expected therapeutic range based on preclinical pharmacokinetic and pharmacodynamic modeling; the filing reports no clinical efficacy findings.
- Risks identified include clinical-development uncertainty; enrollment or dosing delays; adverse events or side effects; financing needs; competition; regulatory approval; manufacturing complexity and third-party manufacturing risks; intellectual-property protection; and reliance on third parties for studies and trials.
- The filing also refers investors to risk factors in CAMP4’s 2025 Form 10-K and other SEC filings. The company disclaims any obligation to update the forward-looking statements.
Important facts for investors to verify
- Whether first-patient dosing occurs by year-end 2026 and whether the ASCEND schedule remains on track.
- Enrollment, cohort sizes, site activation and regulatory or ethics approvals, including EU review status.
- Trial safety, pharmacokinetic and dose-selection findings, and whether the planned exploratory endpoints provide interpretable signals.
- Cash runway, financing plans and subsequent financial disclosures, which are not provided in this 8-K.
- Progress toward the SHANK3 development-candidate selection planned for 2027.